Biodesix, Inc. BDSX
19.84 USD -1.65 (-7.68%)
At closeNov 5, 2026, 7:12 PM EST
14.00 -5.84 -29.44%
After hours · Nov 5, 7:12 PM ET
19.07 Day range 21.10
5.46 52-week range 30.60
- YTD
- +191.76%
- 1 year
- +130.70%
News
benzinga.com Biodesix Q3 2026 Earnings Call Transcript Biodesix (NASDAQ:BDSX) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Biodesix Lowers FY2026 Sales Guidance from $108.000M-$114.000M to $101.000M-$103.000M vs $111.817M Est Biodesix (NASDAQ:BDSX) lowers FY2026 sales outlook from $108.000 million-$114.000 million to $101.000 million-$103.000 million vs $111.817 million estimate.
globenewswire.com Biodesix to Participate in Upcoming Investor Conferences LOUISVILLE, Colo., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present…
zacks.com All You Need to Know About Biodesix (BDSX) Rating Upgrade to Buy Biodesix (BDSX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com Will Biodesix, Inc. (BDSX) Report Negative Earnings Next Week? What You Should Know Biodesix (BDSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
globenewswire.com Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026 LOUISVILLE, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third…
benzinga.com Biodesix Announces That The American College Of Chest Physicians Has Published A New Framework For Clinical Practice, "Building A Lung Nodule Program: From Detection To Diagnosis." Biodesix, Inc (NASDAQ:BDSX), a leader in diagnostic solutions, today announced that the American College of Chest Physicians (CHEST) has published a new framework for clinical practice, "Building a…
globenewswire.com American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification New CHEST framework developed by a renowned multidisciplinary panel with expertise in building and managing lung nodule programs across diverse clinical practices New CHEST framework developed by a…
benzinga.com Biodesix Adds AI-Powered Imaging Test To Expand Lung Cancer Risk Screening Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostics solutions company, today announced the addition of Digital Diagnostics to its Lung Diagnostics strategy, establishing the foundation for a…
globenewswire.com Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers Partnership with Vanderbilt University and Vanderbilt Health accelerates development of the first radiomics-based test for lung nodule risk assessment Partnership with Vanderbilt University and…
benzinga.com TD Cowen Maintains Buy on Biodesix, Raises Price Target to $40 TD Cowen analyst Dan Brennan maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $30 to $40.
benzinga.com Biodesix Announces Multiple Presentations At CHEST 2026 Highlighting How Nodify Lung Testing Is Being Incorporated Into Real-World Lung Nodule Management The presentations build upon the strong evidence base with new use cases and clinical comparisons, illustrating how blood-based lung nodule risk assessment guides clinical decision-making, affects…
globenewswire.com Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026 New sponsored and independent research evaluates clinical utility, patient follow-up, and diagnostic test sequencing New sponsored and independent research evaluates clinical utility, patient…
zacks.com Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests BDSX advances two blood-based MRD programs with Bio-Rad and Thermo Fisher to broaden access to cancer monitoring.- benzinga.com Biodesix Announces Progress In Two Collaborative Programs For Tumor-informed And Tumor-naïve Molecular Residual Disease Solutions Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostics solutions company, today announced strategic progress in two collaborative programs for tumor-informed and tumor-naïve Molecular Residual Disease…
globenewswire.com Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring Biodesix-led tumor-informed and tumor-naïve programs draw on the company's bioinformatics and diagnostics test development expertise Biodesix-led tumor-informed and tumor-naïve programs draw on the…
globenewswire.com Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules Industry-leading QA/RA excellence accelerates…
defenseworld.net Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Recommendation of “Moderate Buy” by Analysts Biodesix, Inc. (NASDAQ: BDSX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the five analysts that are presently covering the firm, Marketbeat Ratings reports. One…
globenewswire.com Biodesix to Participate in Upcoming Investor Conferences LOUISVILLE, Colo., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present…
zacks.com What Makes Biodesix, Inc. (BDSX) a Strong Momentum Stock: Buy Now? Does Biodesix, Inc. (BDSX) have what it takes to be a top stock pick for momentum investors? Let's find out.
zacks.com Wall Street Analysts See a 26.72% Upside in Biodesix (BDSX): Can the Stock Really Move This High? The consensus price target hints at a 26.7% upside potential for Biodesix (BDSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings…
zacks.com PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now? Precipio and Biodesix take different approaches to cancer diagnostics, but which stock looks more compelling now? Let's dive in.
marketbeat.com Biodesix Sees Nodify Growth, Reaffirms Revenue Outlook at Canaccord Conference Biodesix NASDAQ: BDSX said its commercial expansion, broader primary care outreach and recently published clinical data supporting use of its Nodify CDT test in smaller lung nodules are among the…
zacks.com Biodesix, Inc. (BDSX) Hit a 52 Week High, Can the Run Continue? Biodesix (BDSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
zacks.com Wall Street Analysts Think Biodesix (BDSX) Could Surge 31.91%: Read This Before Placing a Bet The consensus price target hints at a 31.9% upside potential for Biodesix (BDSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings…- benzinga.com Canaccord Genuity Maintains Buy on Biodesix, Raises Price Target to $35 Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $27 to $35.
benzinga.com HC Wainwright & Co. Maintains Buy on Biodesix, Raises Price Target to $27 HC Wainwright & Co. analyst Yi Chen maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $26 to $27.
seekingalpha.com Biodesix, Inc. (BDSX) Q2 2026 Earnings Call Transcript Biodesix, Inc. (BDSX) Q2 2026 Earnings Call Transcript
marketbeat.com Biodesix Q2 Earnings Call Highlights Biodesix NASDAQ: BDSX reported second-quarter 2026 revenue growth of 34% year over year, supported by increased diagnostic test volumes, higher average revenue per test and continued expansion of its…
benzinga.com Biodesix Affirms FY2026 Sales Guidance of $108.000M-$114.000M vs $110.996M Est Biodesix (NASDAQ:BDSX) affirms FY2026 sales outlook from $108.000 million-$114.000 million to $108.000 million-$114.000 million vs $110.996 million estimate.- benzinga.com Roth Capital Initiates Coverage On Biodesix with Buy Rating, Announces Price Target of $32 Roth Capital analyst Max Masucci initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating and announces Price Target of $32.
- benzinga.com Canaccord Genuity Maintains Buy on Biodesix, Raises Price Target to $27 Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $22 to $27.
benzinga.com This ICU Medical Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed outlook on top names. Find all rating changes on Benzinga's analyst ratings page. See analyst views on ICUI, BDSX,.- benzinga.com HC Wainwright & Co. Initiates Coverage On Biodesix with Buy Rating, Announces Price Target of $26 HC Wainwright & Co. analyst Yi Chen initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating and announces Price Target of $26.
benzinga.com Canaccord Genuity Maintains Buy on Biodesix, Raises Price Target to $22 Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $20 to $22.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Biodesix Q1 2026 Earnings Call: Complete Transcript 
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com Biodesix Raises FY2026 Sales Guidance from $106.000M-$112.000M to $108.000M-$114.000M vs $108.680M Est Biodesix (NASDAQ:BDSX) raises FY2026 sales outlook from $106.000 million-$112.000 million to $108.000 million-$114.000 million vs $108.680 million estimate.
- benzinga.com Biodesix Q1 EPS $(0.81) Beats $(1.12) Estimate, Sales $25.555M Beat $23.178M Estimate Biodesix (NASDAQ:BDSX) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(1.12) by 27.68 percent. This is a 49.38 percent increase over losses of $(1.60)…
benzinga.com Earnings Scheduled For May 4, 2026 - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com Biodesix Earnings Report: Q4 Overview - benzinga.com Biodesix Sees FY2026 Sales $106.000M-$112.000M vs $105.624M Est 2026 Financial OutlookThe Company anticipates generating between $106-112 million in total revenue in 2026, the mid-point representing 23% growth over 2025 total revenue, and expects continued…
benzinga.com Biodesix Q4 EPS $(0.49) Beats $(0.85) Estimate, Sales $28.755M Beat $25.728M Estimate Biodesix (NASDAQ:BDSX) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.85) by 42.69 percent. This is a 56.64 percent increase over losses of $(1.13)…- benzinga.com Earnings Scheduled For February 26, 2026
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com Market-Moving News for January 12th XOM: -1.5% | Trump 'Inclined' To Keep Exxon Mobil Out Of Venezuela: 'Didn't Like Their Response' BDSX: 46% | Biodesix Sees Q4 Revenue $28.8M, FY2025 Revenue $88.5M, Up 41% and 24% YoY CRML: 15% |
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session